MAPS Congratulates Lykos Therapeutics on Acceptance of New Drug Application for MDMA-Assisted Therapy for PTSD The FDA has accepted Lykos Therapeutics' New Drug Application, supported by two decades of research incubated by MAPS, for MDMA-assisted therapy for PTSD.

MAPS Welcomes New Investors, Name Change for MAPS Public Benefit Corporation MAPS shares ownership of Lykos with mission-aligned investors, will continue to advance psychedelic research, change drug policy, and shape culture

MAPS Celebrates Submission of New Drug Application to FDA for MDMA-Assisted Therapy for PTSD The first NDA submission for any psychedelic-assisted therapy has been submitted through a 30-year effort initiated and led by the nonprofit MAPS

MAPS Receives $5 Million Grant from the Steven & Alexandra Cohen Foundation SAN JOSE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for Psychedelic Studies (MAPS) today announced that the Steven & Alexandra Cohen Foundation has awarded MAPS...

Psychedelic-Assisted Therapies Allowed in Australia Through Special Access Scheme SAN JOSE, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- The Therapeutic Goods Administration (TGA) in Australia announced today that they will permit limited use of certain psychedelic-assisted...